Cerecor competitors

Dr. Tabuteau has served as our founder, Chief Executive Officer, and Chairman of our board of directors since our founding in January 2012. Prior to founding our company, Dr. Tabuteau was a Senior Analyst and Partner at Healthco/S.A.C. Capital (now known as HealthCor) where he was responsible for the biotechnology, genomics, and instrumentation portfolios. Previously, Dr. Tabuteau was the healthcare analyst at Kingdon Capital. Prior to that position, Dr. Tabuteau was a Senior Research Analyst at Banc of America Securities covering the hospital supplies sector. Prior to Banc of America, Dr. Tabuteau was part of the healthcare investment banking group at Goldman Sachs. Dr. Tabuteau earned his M.D. from Yale University School of Medicine and his Bachelor of Arts in molecular biology and biochemistry from Wesleyan University.

Tom co-founded Dermira in 2010 and is our Chief Executive Officer and Chairman of our board of directors. Tom brings over 25 years of experience in specialty pharma and 18 years of experience in dermatology. Prior to founding Dermira, Tom served as Chairman of the board of directors and Chief Executive Officer of Peplin, Inc. until Peplin’s acquisition by LEO Pharma A/S in 2009. Previously, Tom served as Chairman of the board of directors and Chief Executive Officer of Connetics Corporation until Connetics was acquired by Stiefel Laboratories, Inc. in 2006. Prior to Connetics, Tom served as President and Chief Operating Officer of CytoTherapeutics Inc., and in various management positions at Ares-Serono S.A., including President of its U.S. pharmaceutical operations and Managing Director of its U.K. pharmaceutical operations. Tom began his career with Eli Lilly and Company. Tom has served on the boards of various industry organizations, educational institutions and private and public companies, including service on the boards of directors of Onyx Pharmaceuticals, Inc., until its acquisition by Amgen in 2013, Sangamo Biosciences, Inc., Lithera and Somaxon Pharmaceuticals, Inc. In addition, Tom is Chairman of the Biotechnology Institute, a non-profit educational organization, and is a member of the board of trustees of the University of Kansas Endowment Association. Tom holds a B.S. in pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University.

Joshua M. Tarnoff is a CEO at JDP Therapeutics Inc.

• Member of the National Ernst and Young Entrepreneur of the Year Hall of Fame• Inducted into the University of Texas College of Natural Sciences Hall of Honor• Received Ohio University's School of Business Distinguished Business Award• Received Ohio University Konneker Medal, the highest award given to a faculty member or former student for entrepreneurial excellence• Named one of the top 10 Life Sciences CEOs in Texas by the Texas Healthcare and Bioscience InstituteMr. Hawkins is currently the President and CEO of Lumos Pharma, Inc. an early-stage orphan drug company based in Austin, Texas. He currently serves as a Board of Director for SciClone Pharmaceuticals Inc., a NASDAQ listed company (SCLN), a biopharmaceutical company whose lead product Zadaxin, an adjuvant for the influenza vaccine in immunocompromised patients or as an immune stimulant, has been approved in at least 13 countries.In addition he serves as a Board of Director for Cytori Therapeutics, Inc.; a global leader in stem cell research and the use of adipose derived stem and regenerative cells.Rick Hawkins is a member of the National Ernst and Young Entrepreneur of the Year Hall of Fame.Mr. Hawkins was inducted into the Hall of Honor for the College of Natural Sciences at the University of Texas by Dean, Mary Ann Rankin. In 2006 he received Ohio University’s Distinguished Business Achievement Award, and in 2014 was awarded the Konneker Medal, the leading entrepreneurial honor awarded by the University. Rick was named one the top 10 Life Sciences CEO’s in Texas by the Texas Healthcare & Bioscience Institute and was the keynote speaker at BioVenture Showcase 2008.